An evaluation of cyclosporine ophthalmic solution 0.09% vs cyclosporine ophthalmic emulsion 0.05% on tear volume in an NOD mice model

被引：0
|
作者：
Luchs, Jodi [1 ]
Burade, Vinod [2 ]
Zalawadia, Rishit [2 ]
Patel, Alpesh [2 ]
Ogundele, Abayomi B. [3 ]
机构：
[1] Florida Vis Inst, W Palm Beach, FL USA
[2] Sun Pharmaceut Ind Ltd, Mumbai, Maharashtra, India
[3] Sun Pharmaceut Ind Ltd, Princeton, NJ USA
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2020年 / 61卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
105
引用
收藏
页数：3
相关论文
共 35 条
  • [21] The IMPAPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye
    Stonecipher, Karl G.
    Torkildsen, Gail L.
    Ousler, George W., III
    Morris, Scot
    Villanueva, Linda
    Hollander, David A.
    CLINICAL OPHTHALMOLOGY, 2016, 10 : 887 - 895
  • [22] An investigation of 0.05% cyclosporine ophthalmic emulsion in reducing ocular surface staining and impact on visual performance in individuals with dry eye
    Torkildsen, Gail
    Stonecipher, Karl
    Ousler, George W.
    Villanueva, Linda
    Hollander, David A.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [23] PERSIST: Physician's Evaluation of Restasis (R) Satisfaction in Second Trial of topical cyclosporine ophthalmic emulsion 0.05% for dry eye: a retrospective review
    Mah, Francis
    Milner, Mark
    Yiu, Samuel
    Donnenfeld, Eric
    Conway, Taryn M.
    Hollander, David A.
    CLINICAL OPHTHALMOLOGY, 2012, 6 : 1971 - 1976
  • [24] Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model
    Spangler, DL
    Bensch, G
    Berdy, GJ
    CLINICAL THERAPEUTICS, 2001, 23 (08) : 1272 - 1280
  • [25] Evaluation of 0.05% Cyclosporine Ophthalmic Emulsion on Ocular Surface Staining and Visual Function in Subjects Who Experience Discomfort While Engaging in Electronic Visual Tasking
    Stonecipher, Karl
    Torkildsen, Gail
    McLaurin, Eugene B.
    Villanueva, Linda
    Ousler, George W.
    Hollander, David A.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [26] Impact of Vehicle Physicochemical Properties on Modeling-Based Predictions of Cyclosporine Ophthalmic Emulsion Bioavailability and Tear Film Breakup Time
    Walenga, Ross L.
    Babiskin, Andrew H.
    Zhang, Xinyuan
    Absar, Mohammad
    Zhao, Liang
    Lionberger, Robert A.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 108 (01) : 620 - 629
  • [27] Efficacy of 0.05% Cyclosporine-A eye drops (II) and 3% Diquafosol ophthalmic solution in the treatment of dry eye after cataract surgery
    Lu, Hongwei
    Zhang, Shuangmei
    Shao, Chenjun
    Chen, Pengfei
    Ma, Minting
    Hao, Yuhua
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2024, 40 (11) : 2689 - 2694
  • [28] NOVATIVE: A Phase II/III, Multicenter, Double-masked, Randomized Study of Cyclosporine A 0.05% and 0.1% Ophthalmic Cationic Emulsion Versus Vehicle in Patients with Vernal Keratoconjunctivitis
    Leonardi, Andrea
    Pisella, Pierre-Jean
    Benitez-del-Castillo, Jose Manuel
    Amrane, Mourad
    Ismail, Dahlia
    Doan, Serge
    Bremond-Gignac, Dominique
    CLINICAL THERAPEUTICS, 2023, 45 (12) : 1284 - 1288
  • [29] Matching-adjusted indirect comparison of phase 3 clinical trial outcomes: OC-01 (varenicline solution) nasal spray and cyclosporine a 0.05% ophthalmic emulsion for the treatment of dry eye disease
    Visco, Denise M.
    Hendrix, Laura H.
    Sun, Lucille
    Tam, Iris
    Macsai, Marian
    Gibson, Andrea A.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2022, 28 (08): : 892 - 902
  • [30] Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years
    Barber, LD
    Pflugfelder, SC
    Tauber, J
    Foulks, GN
    OPHTHALMOLOGY, 2005, 112 (10) : 1790 - 1794
1234